Absorption kinetics of low-dose chewable aspirin - implications for acute coronary syndromes

European Journal of Clinical Investigation

Volumn 45, Issue 1, 2015, Pages 13-17

  Hobl, Eva Luise ^a   Schmid, Rainer W ^a   Stimpfl, Thomas ^a   Ebner, Josef ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute coronary syndromes; Low dose chewable aspirin; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; SALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHEWING GUM;

ACUTE CORONARY SYNDROME; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPEDANCE AGGREGOMETRY; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ADOLESCENT; AGED; CHEWING GUM; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ASPIRIN; CHEWING GUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84921038809     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12373     Document Type: Article

References (28)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
2. Bochner F, Lloyd JV. Aspirin for myocardial infarction. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1995;28:433-8.
3. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010;159:502-17.
4. Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J 2009;157:412-22.
5. Hjemdahl P. Aspirin resistance testing not ready for "prime time". Heart 2009;95:1220-2.
6. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-84.
7. Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985;10:164-77.
8. Mullangi R, Sharma K, Srinivas NR. Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices. Biomed Chromatogr 2012;26:906-41.
9. Montgomery PR, Sitar DS. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Biopharm Drug Dispos 1986;7:21-5.
10. O'Connor RE, Brady W, Brooks SC, Diercks D, Egan J, Ghaemmaghami C, et al. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S787-817.
11. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
12. Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 1978;62:867-72.
13. Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1983;8:297-331.
14. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol 1985;19:675-84.
15. Levy G. Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol 1980;10(Suppl 2):285S-90S.
16. Gibson T, Zaphiropoulos G, Grove J, Widdop B, Berry D. Kinetics of salicylate metabolism. Br J Clin Pharmacol 1975;2:233-8.
17. Lucker PW, Wetzelsberger N, Schettler T, Rogalla K. Pharmacokinetics and relative bioavailability of a new chewable, buffered acetylsalicylic acid tablet formulation in comparison to a conventional plain tablet. Methods Find Exp Clin Pharmacol 1992;14:805-11.
18. Loprete L, Leuratti C, Scarsi C, Radicioni M. Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic Acid in comparison with an oral solution after single-dose administration to healthy volunteers: a phase I, two-way crossover study. Clin Drug Invest 2014;34:19-25.
19. Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995;35:1181-6.
20. Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988;35:287-94.
21. Hobl EL, Jilma B, Ebner J, Schmid RW. Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by isocratic high-pressure liquid chromatography with post-column hydrolysis and fluorescence detection. Biomed Chromatogr 2013;27:695-8.
22. Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009;102:397-403.
23. ISIS-2 CG. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-60.
24. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
25. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13.
26. Kenaan M, Seth M, Aronow HD, Wohns D, Share D, Gurm HS. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013;62:2083-9.
27. Fuchs I, Spiel AO, Frossard M, Derhaschnig U, Riedmuller E, Jilma B. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. Crit Care Med 2010;38:1423-9.
28. Nordt SP, Clark RF, Castillo EM, Guss DA. Comparison of three aspirin formulations in human volunteers. West J Emerg Med 2011;12:381-5.